Puneet Braich
Ophthalmology · Danville, ILNPI 1184908691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,963 of the $73,865 with a category attached, or 69.0%. Amgen accounts for 88.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $34,975 and has fallen 82.3% since, to $6,192 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $369.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$65K
- Alcon$5K
- Carl Zeiss Meditec USA, Inc.$1K
- AbbVie$499
- Regeneron Healthcare Solutions, Inc.$265
- Ivantis, Inc$238
- plus $1K from 16 others
What the payments were for
- Consulting fees$9,65013%
- Speaking & faculty fees$50,96369%
- Travel & lodging$7,34810%
- Food & beverage$5,8948%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 92 | $65,292 |
| Alcon | 33 | $5,370 |
| Carl Zeiss Meditec USA, Inc. | 6 | $1,089 |
| AbbVie(2 entities) | 21 | $499 |
| Regeneron Healthcare Solutions, Inc. | 4 | $265 |
| Ivantis, Inc | 2 | $238 |
| Sun Pharmaceutical Industries Inc. | 9 | $208 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $194 |
| Alimera Sciences, Inc. | 4 | $150 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 2 | $83 |
| Dompe US, Inc. | 3 | $80 |
| Rxsight Inc | 3 | $65 |
| Tarsus Pharmaceuticals, Inc. | 3 | $64 |
| Aerie Pharmaceuticals, Inc. | 4 | $62 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Oyster Point Pharma, Inc. | 2 | $40 |
| Harrow Eye, LLC | 1 | $23 |
| Sight Sciences, Inc. | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$63,077
- Centurion$4,550
- ARTEVO 800$999
- CIRRUS HD-OCT$313
- IOLMaster 700$313
- VisuMax$313
- QUATERA 700$313
- Hydrus Microstent$238
- AcrySof UltraSert$159
- AcrySof IQ PanOptix$146
- EYLEA HD$118
- EYLEA$110
How this compares
$73,865 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 67 | $41,620 |
| RocklatanNetarsudil Mesylat/Latanoprost | 74 | $34,941 |
| RestasisCyclosporine | 15 | $19,903 |
| Cyclosporine | 18 | $14,538 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 46 | $14,474 |
| Travoprost | 22 | $5,438 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $5,095 |
| Latanoprost | 253 | $4,865 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $4,647 |
| Timolol Maleate | 154 | $3,938 |
| Brimonidine Tartrate | 80 | $3,912 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 75 | $2,343 |
| Prednisolone Acetate | 49 | $2,282 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 33 | $1,886 |
| Dorzolamide Hcl | 67 | $1,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $499 | $66,61796 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $62 | $34,94174 claims |
| AlconSimbrinza | $5,370 | $14,47446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Danville
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.